Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.

Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296

Preview

Text jco.20.03296.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (615kB) | Preview

PURPOSE

The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990.

MATERIALS AND METHODS

Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North America, and Australia. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS). The survival estimates were updated for the current era. Additionally, a novel prognostic model for PFS was developed in 3,543 patients with complete information on potentially relevant variables. The results were validated in an independent data set.

RESULTS

Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92% (90%-94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75% (71%-79%) versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In patients with poor prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to 56) and the OS from 48% (95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic model was developed and independently validated. This model identified a new cutoff of lactate dehydrogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional adverse prognostic factors. An online calculator is provided (https://www.eortc.org/IGCCCG-Update).

CONCLUSION

The IGCCCG Update model improves individual prognostication in metastatic nonseminomatous germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG classification as adverse prognostic factors.

Interest & Impact

Downloads

64 since deposited on 28 Sep 2021
25 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item